Oxybutynin, CAS# 5633-20-5, is known as the brand name Oxytrol. Marketed by Watson, this medication used to treat overactive bladder has a patent expiration of Apr 26, 2015. As an industry standard used to treat the symptoms of overactive bladder, also known as OAB, oxybutynin has proven to be both efficacious and safe. As the only bladder control medication that is available in the form of a patch, oxybutynin (Oxytrol) is an essential solution to the embarrassing and often disabling condition of OAB. People who suffer from overactive bladder endure sudden involuntary contractions of the bladder, which leads to symptoms like a frequent, sudden, unstoppable need to urinate, as well as an increased urinary urgency and frequency. Patients diagnosed with bladder control problems such as OAB often find themselves limiting their participation in both physical and social activities, for fear of embarrassment.
As an oxybutynin transdermal system, this patch was developed to deliver oxybutynin continuously and consistently for between a 3 and 4 day period, after it is applied to intact skin. Adverse reactions reported form the use of the oxybutynin patch include skin irritation at the patch site, dry mouth, constipation, diarrhea, and abnormal vision changes. Patients with narrow-angle glaucoma, urinary or gastric retention, or who are allergic to oxybutynin should not use this patch. The oxybutynin transdermal patch should always be applied to intact and dry skin, with the hip, buttock or abdomen being ideal sites for administration. A different application site should be selected as each new patch is applied. The dose of the oxybutynin transdermal patch is one 3.9 milligram a day system, which should be applied twice a week, or every 3-4 days.
Oxybutynin is effectual as it blocks specific receptors called muscarinic receptors in the bladder, and helps to relax the muscles of the bladder. Because OAD is often due to frequent and uncontrollable bladder muscle contractions, oxybutynin helps to relieve these symptoms by acting as an antimuscarinic or anticholinergic treatment. Clinical studies have been favorable for the use of oxybutynin, showing that patients who were dosed with this medical patch had a significantly reduced frequency of wetting accidents. In addition, patients enrolled in several clinical trials reported using the bathroom less frequently and being able to hold and pass a greater amount of urine each time they eliminated. The first segment of a Phase 3 study sponsored by Watson indicated a 61 percent reduction in weekly incontinence episodes for patients who received oxybutynin, after a 3 month period. Daily incontinence episodes were reduced by an astounding 75 percent in patients who received oxybutynin.
According to The National Association for Continence, urinary incontinence affects 200 million people worldwide. Surprisingly one-third of men and women between the ages of 30 and 70 believe that incontinence is a part of aging to accept. Roughly 17 percent of women and 16 percent of men over age 18 have symptoms of OAB. These startling statistics are sure to grow with the aging population, thus requiring the need for generic options for medications to treat patients who don’t wish to stop living due to an overactive bladder. Researchers and developers can obtain API Oxybutynin from LGM Pharma, a reliable and trusted source for all of your R&D needs.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.